Sofgen Pharma

Sofgen Pharma EBITDA per Share

The EBITDA per Share of Sofgen Pharma (PROCF) as of Oct 18, 2026 is -0.29 USD. In the previous year, EBITDA per Share was 0.39 USD — a change of -173.36% (lower).

EBITDA per Share

-0.29USD

YoY

-173.36%

Last updated:

EBITDA per Share of Sofgen Pharma is 2024 -0.29 USD. EBITDA per Share of Sofgen Pharma was 2023 0.39 USD. It decreases by -173.36% lower compared to the previous year.

The Sofgen Pharma EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
0.33 USD
Jan 1, 2020
0.61 USD
Jan 1, 2021
0.62 USD
Jan 1, 2022
0.38 USD
Jan 1, 2023
0.39 USD
Jan 1, 2024
-0.29 USD
The Sofgen Pharma EBITDA per Share history
YEAREBITDA per ShareYoY
-0.29USD-173.36%
0.39USD+2.69%
0.38USD-38.80%
0.62USD+1.93%
0.61USD+84.76%
0.33USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sofgen Pharma Stock analysis

What does Sofgen Pharma do? Sofgen Pharma SA, listed under the ticker PROCF with ISIN LU2376511205, is a pharmaceutical company headquartered in Luxembourg. The company operates within the Health Care sector, specifically in the Pharmaceuticals industry. Sofgen Pharma employs approximately 5,500 people and completed its initial public offering on December 9, 2019. The company's website is https://www.procapsgroup.com/. Sofgen Pharma SA develops, manufactures, and sells prescription drugs and products featuring unique combinations and pharmaceutical forms, alongside nutritional supplements such as omega-3 fish oils and high-potency clinical compounds. The company organizes its operations through five business units: Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics focuses on diabetes solutions. Farma Procaps is involved in formulating, manufacturing, and marketing branded prescription drugs in Latin America. Softi Gel offers contract drug development and manufacturing services to other pharmaceutical companies. Vital Care specializes in developing, manufacturing, and marketing consumer healthcare products. Clinical Specialties is dedicated to the development, manufacturing, and marketing of complex drugs. The company's business model emphasizes specialized pharmaceutical solutions and consumer health products, with a global operational footprint. Sofgen Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sofgen Pharma stock

EBITDA per Share of Sofgen Pharma is -0.29 USD in 2024.

EBITDA per Share of Sofgen Pharma changed from 0.39 USD to -0.29 USD, representing a -173.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Sofgen Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Sofgen Pharma

All Key Metrics — Sofgen Pharma